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The transcription factor nuclear factor erythroid 2 p45-related
factor 2 (Nrf2) is the master regulator of the cellular redox
homeostasis. Nrf2 target genes comprise of a large network of
antioxidant enzymes, proteins involved in xenobiotic detoxifi-
cation, repair and removal of damaged proteins, inhibition of
inflammation, as well as other transcription factors. In recent
years it has emerged that as part of its role as a regulator of
cytoprotective gene expression, Nrf2 impacts mitochondrial
function. Increased Nrf2 activity defends against mitochondrial
toxins. Reduced glutathione, the principal small molecule
antioxidant in the mammalian cell and a product of several of
the downstream target genes of Nrf2, counterbalances mito-
chondrial ROS production. The function of Nrf2 is suppressed
in mitochondria-related disorders, such as Parkinson’s disease
and Friedrich’s ataxia. Studies using isolated mitochondria and
cultured cells have demonstrated that Nrf2 deficiency leads to
impaired mitochondrial fatty acid oxidation, respiration and ATP
production. Small molecule activators of Nrf2 support mito-
chondrial integrity by promoting mitophagy and conferring
resistance to oxidative stress-mediated permeability transition.
Excitingly, recent studies have shown that Nrf2 also affects
mitochondrial function in stem cells with implications for stem
cell self-renewal, cardiomyocyte regeneration, and neural
stem/progenitor cell survival.
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The mitochondria are known as the powerhouse of the
cell. The process of providing the cell with the bulk of
its energy is intimately linked to the production of
reactive oxygen species (ROS) during oxidative phos-
phorylation. In most cells, the mitochondria and
NADPH oxidase are the main sources of ROS. Our
understanding of the role of ROS within the cell is
becoming increasingly complex. The traditional view of
ROS simply being a harmful by-product of respiration is
giving way to a more intricate picture where the role of
ROS as an important signaling molecule is emerging
[1,2]. It is however becoming evident that an imbalance
in the generation of ROS is a common feature in several
disease states, ranging from neurodegeneration and
diabetes to cardiovascular disease and cancer [3].
As the master regulator of the cellular redox homeostasis,
the cap ‘n’ collar basic leucine zipper (CNC-bZip) tran-
scription factor, nuclear factor erythroid 2 p45-related
factor 2 (Nrf2) is well equipped to counterbalance the
mitochondrial ROS production and is critical for main-
taining the redox balance in the cell [4]. Following
exposure to oxidants or electrophiles, Nrf2 accumulates
in the nucleus. There, it binds to antioxidant response
elements (ARE) in the upstream regulatory regions of
genes encoding detoxification and antioxidant enzymes,
leading to their enhanced transcription [4e6].Work from
our laboratories and the laboratories of other in-
vestigators, has shown that the status of Nrf2 activity
affects mitochondrial function, and this has been
reviewed [7e10]. The current opinion article briefly sum-
marizes the available experimental evidence and provides
an update of the most recent findings in this area.2. Nrf2 regulation
Under basal conditions, Nrf2 is rapidly turned over, and
the function of Nrf2 is primarily regulated by controlling
the protein levels of the transcription factor through
ubiquitination and proteasomal degradation. There are
three known ubiquitin ligase systems that are respon-
sible for Nrf2 degradation (Figure 1). The first discov-
ered and most studied is the Kelch-like ECH-associated
protein 1 (Keap1)eCullin3 (Cul3)/Rbx1 [11e13]. As a
negative regulator of Nrf2 [14], Keap1 serves as a sub-
strate adaptor protein for the ubiquitin ligase Cul3/
Rbx1. Keap1 binds Nrf2 in the cytoplasm and targets
the transcription factor for ubiquitination and protea-
somal degradation, maintaining Nrf2 at a low steady
state level. Oxidants and electrophiles react withwww.sciencedirect.com
Figure 1
Regulation of Nrf2 under homeostatic conditions. Nrf2 is a short-lived protein that is continuously targeted for ubiquitination and proteasomal
degradation. Three known ubiquitin ligase systems mediate the degradation of Nrf2: Kelch-like ECH associated protein 1 (Keap1), a substrate adaptor
protein for Cullin3 (Cul3)/Rbx1-based Cullin–RING E3 ubiquitin ligase and a cysteine-based sensor for Nrf2 inducers; b-transducin repeat-containing
protein (b-TrCP), a substrate adaptor for Skp1–Cullin1 (Cul1)/Rbx1-based Cullin–RING E3 ubiquitin ligase; and the E3 ubiquitin ligase Hrd1 which
resides in the endoplasmic reticulum (ER). The relative contributions of these systems towards the degradation of Nrf2 depend on the specific conditions.
Degradation mediated by Keap1 requires reduced state of its cysteine sensors. Degradation mediated by b-TrCP requires prior phosphorylation of Nrf2 by
glycogen synthase kinase 3 (GSK3). Degradation mediated by Hrd1 occurs during ER stress.
Role of Nrf2 in mitochondrial function Holmström et al. 81cysteine sensors within Keap1 [15e17], causing a
conformational change [18,19] and the inability of
Keap1 to target Nrf2 for degradation [20]. This allows
free Nrf2 to accumulate and translocate to the nucleus
where it binds to a small Maf protein, activating the
expression of its target genes [21,22]. Nrf2 is also sub-
ject to degradation following phosphorylation by
glycogen synthase kinase 3 (GSK3) via b-transducin
repeats-containing protein (b-TrCP)-Cul1-based ubiq-
uitin ligase [23,24]. The most recently described
ubiquitin-dependent system involved in Nrf2 degrada-
tion is the E3 ubiquitin ligase synoviolin (Hrd1), which
resides in the endoplasmic reticulum [25].
Besides regulation of Nrf2 through its degradation, the
function of the transcription factor is also controlledwww.sciencedirect.comthrough the spatial distribution of both Nrf2 and Keap1.
There are three pools of Nrf2 within the cell. In addition
to the predominant cytoplasmic pool, there is a nuclear
pool of Nrf2, the redistribution of which is controlled in
part by Keap1-mediated degradation and by Nrf2 nu-
clear import signals and mediators [26]. Nrf2 and Keap1
have also been detected at the outer mitochondrial
membrane, tethered to the mitochondrial phosphatase
phosphoglycerate mutase family member PGAM5 [27].
The three pools of Nrf2 are highly dynamic and
subjected to a further fine-tuned regulation. Thus, it has
been reported that the ubiquitin-conjugating enzyme
UBE2E3 and its nuclear import receptor importin 11
regulate Nrf2 distribution and activity, by restricting the
transcription factor from partitioning to the mitochon-
dria and limiting its repression by nuclear Keap1 [28].Current Opinion in Toxicology 2016, 1:80–91
82 Oxidative Toxicology3. Nrf2 and the cellular redox homeostasis
Since its discovery in the mid-1990s [22,29], Nrf2 has
been extensively studied. The number of publications on
Nrf2 has exceeded 7000, and continues to increase
exponentially (http://www.ncbi.nlm.nih.gov/pubmed/?
term=nrf2). Nrf2 has been associated with cytopro-
tective functions in animal models of a range of human
disease conditions, and has been implicated in the
regulation of over 600 target genes [30]. Nrf2 targets
include antioxidant enzymes, proteins involved in
xenobiotic metabolism and clearance, protection against
heavy metal toxicity, inhibition of inflammation, repair
and removal of damaged proteins, as well as other tran-
scription and growth factors [31]. Nrf2 regulates the
expression of g-glutamyl cysteine ligase catalytic
(GCLC) andmodulatory (GCLM) subunits, glutathioneFigure 2
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Current Opinion in Toxicology 2016, 1:80–91reductase (GR) [21,30,32e35], as well as the four en-
zymes [i.e. malic enzyme 1 (ME1), isocitrate dehydro-
genase 1 (IDH1), glucose-6-phosphate dehydrogenase
(G6PD), and 6-phosphogluconate dehydrogenase
(6PGD)] that are responsible for the generation of
NADPH [36e40], all of which are involved in the
biosynthesis and maintenance of reduced glutathione
(GSH). In turn, GSH, the principal small molecule
antioxidant in the mammalian cell, counterbalances the
production of ROS. In more recent years, it has emerged
that one of the important functions of Nrf2 is to modu-
late mitochondrial function, as part of its role as a master
regulator of cytoprotective gene expression and the
cellular redox homeostasis (Figure 2). The evidence for
this is two fold. First, it has been shown that the Nrf2
pathway is upregulated and is involved in protectionNADPH
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ases the mitochondrial membrane potential (DJ), the availability of sub-
s of NADPH by enhancing the expression of genes encoding glucose-6-
athway (PPP), malic enzyme 1 (ME1) and isocitrate dehydrogenase 1
k to the mitochondria. Nrf2 also regulates the levels of GSH by enhancing
generation from its oxidized form, GSSG, including glutathione reductase
e, fatty acid synthase, and stearoyl CoA desaturase, four critical enzymes
A may increase mitochondrial fatty acid oxidation (FAO) by relieving its
the transport of long-chain fatty acids into the mitochondria. The red and
The presentation of the structure of each respiratory complex is adapted
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increased Nrf2 activity enhanced resistance to mito-
chondrial toxins such as the complex I inhibitor rotenone
or the complex II inhibitor 3-nitropropionic acid in vitro
and in vivo [41e43]. Second, Nrf2 function has been
reported to be impaired in mitochondria-related disor-
ders, whereas Nrf2 activation has beneficial effects. For
example, the Nrf2 pathway is suppressed in Parkinson’s
disease patient derived olfactory neurosphere cells [44],
and Nrf2 activation restores the glutathione levels in
these cells [45]. This Nrf2 suppression is especially
prominent in Friedrich’s ataxia where Nrf2 activation
upon oxidative stress was found to be blocked in patient
fibroblasts [46].Figure 3
PMI Sulforaphane
RTA-408 Dimethyl fumarate
Examples of small-molecule Nrf2 activators that improve mitochon-
drial function and integrity. Chemical structures of 1-(3-iodophenyl)-4-
(3-nitrophenyl)-1,2,3-triazole (PMI), 1-isothiocyanato-(4R)-(methylsulfinyl)
butane (sulforaphane), N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-
dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2H-
picen-4a-yl)-2-2-difluoro-propionamide (RTA-408, Omaveloxolone) and4. Nrf2 and mitochondrial homeostasis
In 2008, Lo and colleagues reported that Keap1 asso-
ciates with PGAM5, establishing a physical link to
mitochondria [27]. That same year, an association be-
tween Nrf2 and mitochondrial biogenesis was found in
cardiomyocytes, where Nrf2 stimulates the biogenesis
program through activation of nuclear respiratory factor-
1 (NRF-1) [47]. This has since been confirmed in
in vivo studies [48]. What we have been interested
in establishing is a more direct involvement of Nrf2 in
modulating mitochondrial function (recently reviewed
in [7,8,10]). We showed that respiration and ATP levels
are decreased in cells and mitochondria isolated
from Nrf2-knockout (Nrf2-KO) mice, while they are
increased in their Keap1-knockout (Keap1-KO) and
Keap1-knockdown (Keap1-KD) counterparts [49,50].
Similarly, mitochondrial fatty acid oxidation is impaired
in cells and mitochondria isolated from Nrf2-KO mice
[51]. This could potentially be the reason for the higher
accumulation of triglycerides in the liver upon fasting in
these mice [52]. As the activities of the respiratory
enzymes are not impaired [49], the decrease in respi-
ration and ATP levels under conditions of Nrf2 defi-
ciency argue that the main limitation is substrate
availability.
Mitochondrial integrity is key to overall mitochondrial
functionality. Mitophagy has emerged as a way to
maintain the organelle integrity, by selectively removing
damaged mitochondria [53]. One of the critical players
involved in this process is the autophagic adaptor pro-
tein sequestosome-1 (SQSTM1/p62) [54]. p62 in-
teracts with the Nrf2-binding site on Keap1, competing
with Nrf2 for binding [55,56]. This interaction is further
enhanced by phosphorylation [57,58]. Therefore,
increased free p62 levels activate the Nrf2 pathway. p62
is also an Nrf2-target gene, thus creating a positive
regulatory loop [55,56]. An Nrf2-dependent small-
molecule mitophagy inducer (p62-mediated mitophagy
inducer e PMI) (Figure 3) was recently discovered.
PMI directly disrupts the Nrf2-Keap1 interaction [59]
and induces mitophagy independently of dissipation ofwww.sciencedirect.comthe mitochondrial membrane potential and the mito-
chondrial serine/threonine-protein kinase PTEN-
induced kinase 1 (PINK1)/Parkin pathway [60].
When mitochondrial integrity is lost beyond repair, the
mitochondria can undergo permeability transition to
induce cell death [61]. Induction of Nrf2 using the
isothiocyanate sulforaphane (Figure 3) [62,63] confers
resistance to redox-regulated permeability transition
[64], suggesting a further role for the Nrf2 pathway in
maintaining mitochondrial integrity.5. Nrf2, mitochondrial function and
neurological conditions
Neurodegenerative disorders are commonly character-
ized by oxidative stress, mitochondrial dysfunction and
protein misfolding, making them ideal targets for Nrf2
activator mediated therapy (reviewed in [10,65,66]).
Nrf2 activation has long been shown to be cytoprotective
in both toxicological as well as genetic models of neuro-
degeneration in vitro and in vivo [67e76]. More recently,
we have reported that treatment with the Nrf2 inducers
RTA-408, a synthetic cyanoenone triterpenoid, or with
the naturally occurring isothiocyanate sulforaphane
(Figure 3) restored the mitochondrial membrane poten-
tial and protected against dopamine toxicity in primary
co-cultures of midbrain neurons and astrocytes isolated
from PINK1-KO mice, a model of hereditary early-onset
Parkinson’s disease [8]. A wide variety of small molecule
activators of the Nrf2 pathway have been established and
tested in both in vitro and in vivo models of neurodegen-
erative diseases, including multiple sclerosis, Parkinson’s,
Huntington’s and Alzheimer’s disease (recently reviewed
in [77]), showing great promise as potential therapeutic
agents. Sulforaphane has shown protective effects in adimethyl fumarate (BG-12, Tecfidera).
Current Opinion in Toxicology 2016, 1:80–91
Table 1 Protective Activity of Sulforaphane and Its Glucoraphanin Precursor in Rodent Models of Neurological Conditions.
Condition
/disease
Species/strain Damaging agent Sulforaphane dose Efficacy endpoints References
Brain injury Rat _
Sprague Dawley
Controlled cortical impact 5 mg/kg, i.p., 6 h post-
injury
Increase in AQP4 in
penumbra; increase in
GPx in cortex; increase in
GSTa3 and HO-1 in brain
microvessels; decrease in
loss of tight junction
proteins and endothelial
cells; decrease in blood-
brain barrier permeability
and cerebral edema
Zhao et al. (2005, 2007)
[104,105]
Brain injury Rat _
Sprague Dawley
Controlled cortical impact 5 mg/kg, i.p., 15 min post-
injury
Increase in Nrf2, NQO1
and HO-1 in cortex;
decreased oxidative
damage to lipids, proteins
and DNA; decreased brain
contusion volume and
cortical neuronal death;
improved neurologic
function
Hong et al. (2010) [106]
Brain injury Mouse _
C57BL/6
WT and Nrf2−/−
Controlled cortical impact 5 mg/kg, i.p., 6 h post-
injury
Decrease in blood-brain
barrier permeability in WT
mice; Nrf2−/− mice more
sensitive than WT mice &
no protection by SFN
Zhao et al. (2007) [105]
Brain injury Mouse _
ICR
WT and Nrf2−/−
Controlled cortical impact 5 mg/kg, i.p., 15 min post-
injury
Nrf2−/− mice more
sensitive than WT mice &
no protection by SFN
Hong et al. (2010) [106]
Brain injury Rat _
Wistar
Subarachnoid
hemorrhage
5 mg/kg, i.p., 30 min, 12 h,
and 36 h after blood
injection
Increase in Nrf2, NQO1,
GSTa1 and HO-1 in
cortex; decrease in
cerebral edema, blood-
brain barrier impairment,
cortical apoptosis, and
motor deficits
Chen et al. (2011) [107]
Spinal cord
injury
Mouse _
ICR
WT and Nrf2−/−
Contusion injury (vascular
clip, 10 g)
5 mg/kg, i.p.,
1 h after injury
Decrease in MMP9 and
TNFa, vascular
permeability changes,
inflammatory damage,
histologic injury, dying
neurons count, and spinal
cord edema; enhanced
hindlimb locomotor
function;
Nrf2−/− mice more
sensitive than WT mice &
no protection by SFN
Mao et al. (2010, 2011)
[108,109]
Spinal cord
injury
Rat \
Fischer
Contusion injury (weight
drop, 10 g)
5 mg/kg, i.p., 15 min after
injury, then once a day for
3 days
Increase in Nrf2 and
GCLC in spinal cord 1 day
after injury; decrease in IL-
1b, TNFa, IkBa
phosphorylation, and
contusion volume;
improvement in
coordination
Wang et al. (2012) [110]
Spinal cord
injury
Rat \
Sprague-Dawley
Contusion injury (200
kdyn)
10 or 50 mg/kg, i.p.,
10 min and 72 h after
injury
Increase in NQO1 and
HO-1, and decrease in
MMP9 in spinal cord 4 h
after injury; decrease in
urinary MIF activity;
increase in serotonergic
Benedict et al. (2012)
[111]
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Table 1 (continued )
Condition
/disease
Species/strain Damaging agent Sulforaphane dose Efficacy endpoints References
axons caudal to the lesion;
enhanced hindlimb
locomotor function
Stroke Rat _
Long–Evans
Temporary common
carotid/middle cerebral
artery occlusion
5 mg/kg, i.p., 15 min post-
ischemia
Increase in HO-1 in brain;
decrease in infarct volume
Zhao et al. (2006) [112]
Alzheimer’s
disease
Mouse _
ICR
Ab(1-40) injection, i.c.v. 30 mg/kg/day, i.p., from
day −1 to day 4 post-Ab
Decrease in impairment of
working and contextual
memory; no effect on
amyloidogenesis
Kim et al. (2013) [74]
Parkinson’s
disease
Mouse _
C57BL/6
WT and Nrf2−/−
MPTP (for 5 consecutive
days starting on day 0)
50 mg/kg, i.p., on day −1
(2 doses, 8 h apart); then
daily doses on day 1, 3
and 5
Increase in NQO1, HO-1,
GCLC and GCLM in
striatum and ventral
midbrain; decrease in loss
of dopaminergic neurons,
astrogliosis and
microgliosis; decrease in
pro-inflammatory
mediators (IL6 and TNFa);
Nrf2−/− mice more
sensitive than WT mice &
no protection by SFN
Rojo et al. (2010),
Innamoratoet al. (2010),
and Jazwa et al. (2011)
[70,72,113]
Parkinson’s
disease
Mouse _
C57BL6/SJL
MPTP Nrf2−/− mice more
sensitive than WT mice;
protection by Nrf2
overexpression or Keap1
(by siRNA)
downregulation
Chen et al. (2009) and
Williamson et al. (2012)
[68,69]
Parkinson’s
disease
Mouse _
C57BL/6
6-Hydroxy-dopamine-
induced lesion
5 mg/kg, i.p., twice a week
for 4 weeks starting after
lesion induction
Decrease in motor
function deficits; decrease
in degeneration of
dopaminergic neurons
and DNA fragmentation;
increase in GSH and GR
Morroni et al. (2013) [114]
Parkinson’s
disease
Mouse _
C57BL/6
Rotenone 50 mg/kg, i.p., every other
day before rotenone for 60
days
Increase in NQO1, HO-1
and LC3-II in cortex and
striatum compared to
rotenone treatment;
decrease in rotenone-
induced oxidative
damage; decrease in loss
of dopaminergic neurons;
decrease in motor function
deficits
Zhou et al. (2016) [115]
Huntington’s
disease
Rat _
Wistar
2,3-Pyridine-dicarboxylic
acid (quinolinic acid)
5 mg/kg, i.p., 24 h and
5 min before intrastriatal
infusion of quinolinic acid
Increase in GSH, GR, and
GPx; decrease in oxidized
proteins, mitochondrial
dysfunction, striatal
degeneration and circling
behavior
Santana-Martínez et al.
(2014) and Luis-García
et al. (2016) [116,117]
Depression Mouse _
Swiss and C57BL/6
WT and Nrf2−/−
LPS 1 mg/kg, i.p., for 7
consecutive days before
and the day after LPS
Compared to WT mice,
decrease in dopamine and
serotonin levels in
prefrontal cortex,
retraction of astroglial
processes, increased
microgliosis and
depressive phenotype of
Nrf2−/− mice without LPS;
Increase in HO-1, GCLM
Martín-de-Saavedra et al.
(2013) [118]
(continued on next page)
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Table 1 (continued )
Condition
/disease
Species/strain Damaging agent Sulforaphane dose Efficacy endpoints References
and BDNF and decrease
in iNOS by SFN in
hippocampus of in WT
mice with LPS;
Improved depressive-like
behavior in WT mice with
LPS
Depression Mouse _
ICR
Acute stress
Chronic stress
(28 days)
1, 3, or 10 mg/kg/day, i.p.,
for 14 days
10 mg/kg/day, i.p., for 14
days starting on day 14
Reversal of depressive-
and anxiety-like behavior
Decrease in pro-
inflammatory mediators
(IL6 and TNFa) and serum
corticosterone and
adrenocorticotropic
hormone levels; reversal
of depressive- and
anxiety-like behavior
Wu et al. (2016) [119]
Depression Mouse _
C57BL/6
WT and Nrf2−/−
Repeated social defeat
stress for 10 days
10 mg/kg, i.p.,
30 min before defeat
stress
or
0.1% dietary
glucoraphanin
Attenuation of decreased
levels in Keap1, Nrf2,
BDNF, p-TrkB, and
depression-like behavior;
Nrf2−/− mice more
sensitive than WT mice
Yao et al. (2016) [120]
Multiple
sclerosis
Mouse \
C57BL/6
(MOG)35–55 immunization,
followed by Pertussis toxin
50 mg/kg, i.p., every other
day for 22 days
Inhibition of development
and severity of
experimental autoimmune
encephalomyelitis;
increase in HO-1 and
NQO1, and decrease in
oxidative stress in brain;
decrease in MMP9,
inflammatory infiltration
and demyelination in
spinal cord; improved
distribution of claudin-5
and occluding;
preservation of the
blood–brain barrier;
inhibition of antigen-
specific Th17 responses
and enhanced IL10
responses
Li et al. (2013) [121]
Multiple
sclerosis
Mouse _
C57BL/6
MOG35-55 immunization,
followed by Pertussis toxin
10 mg/kg/day, i.p.,
myrosinase-activated
glucoraphanin beginning 1
week before immunization
Decrease in inflammation
(NFkB translocation and
IL1b) and apoptosis (Bax
and caspase 3) in spinal
cord; protection against
body weight loss
Giacoppo et al. (2013)
[122]
Abbreviations: AQP4, aquaporin 4; BDNF, brain-derived neurotrophic factor; GCLC, glutamate cysteine ligase catalytic subunit; GCLM, glutamate cysteine
ligase modulatory subunit; GPx, glutathione peroxidase; GSH, reduced glutathione; GST, glutathione S-transferase; HO-1, heme oxygenase 1; IkBa, nuclear
factor kappa-light-chain-enhancer of activated B cells inhibitor, a; IL, interleukin; LC3, microtubule-associated protein light chain 3; LPS, lipopolysaccharide;
MIF, macrophage inhibitory factor; MMP9, matrix metalloproteinase 9; MOG, myelin oligodendroglial glycoprotein peptide; MPTP, methyl-4-phenyl-1,2,3,6-
tetrahydro-pyridine; NFkB, nuclear factor kappa-light-chain-enhancer of activated B cells; NQO1, NAD(P)H:quinone oxidoreductase 1; SFN, sulforaphane;
TNFa, tumor necrosis factor a; p-TrkB, phosphorylated tropomyosin-receptor-kinase B.
86 Oxidative Toxicologynumber of rodent models of neurological conditions
(Table 1). Several Nrf2 activators are undergoing clinical
trials; one of them, BG-12 (Tecfidera), has already
entered clinical practice. BG-12 is an oral formulation ofCurrent Opinion in Toxicology 2016, 1:80–91the Nrf2 inducer dimethyl fumarate (Figure 3), which is
being used for the treatment of relapsing e remitting
multiple sclerosis in humans [78,79]. Currently, the Nrf2
activatorRTA-408 (Figure 3) is being tested for treatmentwww.sciencedirect.com
Role of Nrf2 in mitochondrial function Holmström et al. 87of Friedrich’s ataxia (ClinicalTrials.gov, NCT02255435).
The potential of GSK3 inhibitors (Tideglusib) in
Alzheimer’s disease was explored in a small Phase II
clinical trial. Although in this trial no overall statistically
significant clinical benefit for the drug was found, it was
noted that there was a significant decrease in the levels of
b-secretase 1 (BACE1) in cerebrospinal fluid in a sub-
group of patients [80].
A recent study reported the ability of sulforaphane to
improve social interaction and verbal communication,
reversing abnormal behavior in young men with autism
spectrum disorder [81]. Interestingly, granulocytes of
children with autism exhibit defects in oxidative phos-
phorylation and reduced gene expression of Nrf2 [82].
In healthy human subjects, metabolic profiling after a
dietary intervention with broccoli as a source of glucor-
aphanin, the precursor of sulforaphane, has indicated
enhanced integration of fatty acid oxidation with the
activity of the TCA cycle [83]. Taken together, these
studies suggest that sulforaphane-mediated Nrf2 acti-
vation may lead to improved mitochondrial function and
thus contribute to reversal of the behavioral abnormal-
ities in autism.6. Nrf2 and mitohormesis
An interesting concept that has grown in popularity is
the involvement of Nrf2 signaling in hormesis. Hormesis
refers to the exposure to low levels of stress such as
ROS, which will prime the cell or organism to better
handle future insults [84]. Mitohormesis more specif-
ically suggests that the mitochondria might be essential
for this process [85]. Nrf2 has been suggested multiple
times to have hormetic potential [84,86,87]. This has
been extensively discussed in the context of nutritional
antioxidants and dietary restriction [88], where it has
been shown that Nrf2 is in part responsible for the
beneficial effects of dietary restriction through activa-
tion of the phase 2 response. SKN-1, the Nrf ortholog in
the nematode Caenorhabditis elegans, has been shown to
be a longevity factor [89,90]. SKN-1 activation reduces
the accumulation of ROS and increases proteasome ac-
tivity, stress resistance, and lifespan [89,91]. The exact
mechanism is not fully understood, but SKN-1 is
responsible for mitochondria-associated redox signaling
[90], and for coupling proline catabolism with fatty acid
oxidation during limited nutrient availability [92].
Most recently, Nrf2 activation was linked to lithium-
mediated lifespan extension in Drosophila melanogaster
[93]. Lithium inhibits GSK3, and this inhibition stabi-
lizes and activates Nrf2 (Figure 1), thus extending the
lifespan of the flies, specifically at low doses. As with any
hormetic response, excessive levels of the toxin, and
even excessive Nrf2 activation, has detrimental conse-
quences and decreases lifespan. This is in line with
the phenotype of the Keap1-KO mice, which diewww.sciencedirect.compostnatally from hyperkeratosis of the esophagus due to
constitutive Nrf2 activation [94], and with the reduced
longevity due to prolonged Nrf2 overexpression in
transgenic Drosophila melanogaster [95].7. Emerging role of Nrf2 in mitochondrial
function in stem cells
Although not an entirely novel concept, 2016 has seen a
surge in high impact publications that have explored the
relationship between Nrf2 and mitochondrial function in
the context of stem cell biology. Decreased levels of Nrf2
were shown to correlate with the decrease in regenerative
capacity of subventricular zone neural stem/progenitor
cells (NSPCs) in the rat [96]. Intriguing work by Khacho
and colleagues [97] suggests that dynamic changes in the
mitochondrial network during neural stem cell develop-
ment induce ROS-dependent Nrf2-mediated transcrip-
tional activation of cell differentiation. The metabolic
reprogramming from oxidative phosphorylation to glyco-
lytic energy production that takes place during the in-
duction of pluripotent stem cells differentiation is also
dependent on ROS-mediated Nrf2 activation [98,99]. In
the heart, Nrf2 is necessary for neonatal myocardial
regeneration after apex resection by activating paired-
like homeodomain transcription factor 2 (Pitx2), which
then activates antioxidant genes as well as components of
the electron transport chain [100].
The age-related decline in the regenerative function of
neural stem/progenitor cells has been causally linked to
decreased expression of Nrf2 [98]. A recent report
found that Nrf2 activity is impaired in the premature
aging disorder Hutchinson-Gilford progeria syndrome
(HGPS) due to progerin sequestration of Nrf2, leading
to subnuclear mislocalization of the transcription factor
[101]. Reactivation of the Nrf2 pathway reverses the
cellular phenotype, including key phenotypes of the
disease, such as reduced viability of mesenchymal stem
cells [101] and impaired autophagy [102], while inac-
tivation of the pathway recapitulates some of the aging
phenotypes in HGPS. Together, these studies show that
Nrf2 is an important player in stem cell biology and cell
senescence, and implicate its role in mitochondrial
function as a possible mechanistic link.8. Concluding remarks and future
directions
Work from a number of independent laboratories has
convincingly demonstrated that the status of Nrf2 ac-
tivity affects many aspects of mitochondrial physiology,
including mitochondrial biogenesis, fatty acid oxida-
tion, respiration, ATP production, redox homeostasis,
as well as the structural integrity and dynamics of this
essential organelle. In parallel to recognizing that many
human pathological conditions and aging are associated
with mitochondrial dysfunction, it is becoming
increasingly apparent that this often coincides withCurrent Opinion in Toxicology 2016, 1:80–91
88 Oxidative Toxicologysuppressed Nrf2 signaling. Most excitingly, the ability
to reactivate Nrf2 by pharmacological agents is a
promising strategy for the prevention or treatment of
chronic degenerative diseases and for achieving healthy
aging. Importantly, pharmacological Nrf2 activators
include phytochemicals (e.g. sulforaphane) that are
present in plants, such as cruciferous vegetables, which
have been an important part of the human diet for
centuries, and are largely responsible for the health-
promoting effects of plant-rich diets. As both insuffi-
cient as well as persistently high Nrf2 activity can have
detrimental consequences, it will be critical to under-
stand what is the appropriate “dose” of Nrf2 activity
that would restore the balance and correct the patho-
logical phenotypes.
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